Weight loss increases all-cause mortality in overweight or obese patients with diabetes
A meta-analysis

Yiqi Chen, MM, Xue Yang, MM, Juyang Wang, MM, Yangshiyu Li, MM, Dou Ying, MM, Huijuan Yuan, MD

Abstract
Background: Overweight and obese patients with diabetes are advised to lose weight to improve their health; however, recent studies have demonstrated that weight loss may be associated with worse long-term survival in patients with diabetes. This meta-analysis aimed to examine the relationships between weight loss and all-cause mortality in overweight or obese individuals with diabetes.

Methods: We searched the PubMed and EMBASE databases from inception to February 2017. We included prospective studies that reported sufficient information to extract mortality-specific relative risks (RRs) with corresponding 95% confidence intervals (CIs). RRs with 95% CIs were pooled using a random-effects model. A subgroup analysis was also performed to explore sources of heterogeneity.

Results: Of the 1652 studies identified, 8 met the inclusion criteria. A total of 18,887 patients were included in this analysis. We found that compared with a stable weight, weight loss was associated with an increased risk of all-cause mortality (RR, 1.15; 95% CI, 1.04 to 1.28) and cardiovascular disease (CVD) mortality (RR, 1.15; 95% CI, 1.02 to 1.29) in overweight or obese adults with diabetes, whereas intentional weight loss was not associated with changes in all-cause mortality (RR, 0.90; 95% CI, 0.67 to 1.22). Weight gain was not associated with changes in all-cause mortality (RR, 1.17; 95% CI, 0.87 to 1.58) or CVD mortality (RR, 0.97; 95% CI, 0.93 to 1.01). Compared with an initial body mass index (BMI) of 25 to 30 kg/m², an initial BMI of >35 kg/m² was associated with increased all-cause mortality (RR, 1.23; 95% CI, 1.01 to 1.50), which was further increased with an initial BMI of >40 kg/m² (RR, 1.50; 95% CI, 1.16 to 1.94).

Conclusion: Our results indicate that weight loss but not weight gain increased all-cause mortality and CVD mortality in overweight or obese adults with diabetes.

Abbreviations: BMI = body mass index, CI = confidence interval, CVD = cardiovascular disease, DM = diabetes mellitus, HR = hazard ratio, RR = relative risk, T2DM = type 2 diabetes mellitus.

Keywords: diabetes, mortality, obese, overweight, weight loss

1. Introduction

In the US, approximately 45% to 65% of patients with type 2 diabetes mellitus (T2DM) are obese.[1] Overweight and obese patients with diabetes mellitus (DM) are advised to lose weight not only to improve their glycemic control, quality of life, mobility, and physical functionality but also to reduce their cardiovascular risk factors, medications required to manage diabetes and long-term healthcare costs.[2,3] Moreover, a recent meta-analysis of data from approximately 20,000 participants concluded that compared with weight stability, weight loss was associated with an increased risk of all-cause mortality.[3] However, these conclusions are not uniformly accepted. Specifically, weight loss may be a notably significant indicator for the development of life-threatening, systemic illness, such as cancer.[4–6] Several studies that suggested that weight loss appeared to be associated with worse long-term survival in patients with diabetes[7] have further complicated this debate. While the reasons for this association are unclear, they may be rooted in the obesity paradox. One study included 10,568 patients with diabetes who were followed for a median of 10.6 years. The results indicated that being overweight was associated with a lower mortality risk, whereas obese patients had a mortality risk similar to that of normal-weight individuals.[8] Consequently, this set of controversial findings casts doubt on current clinical practice guidelines and leaves clinicians with substantial uncertainty regarding the value of weight loss in patients with diabetes. The aim of the present study was to examine the impact of weight loss on all-cause mortality in overweight or obese adults with diabetes and to explore possible reasons for these conflicting results.

2. Materials and methods

2.1. Literature search

The PubMed and EMBASE electronic databases were searched from inception to February 2017 to identify relevant studies. We used a combination of keywords related to the types of weight
loss, diabetes, and mortality. The syntax used for Medline is provided in Table 1. The search strategies used for the other databases were similar, with the necessary adaptations employed. An English language restriction was imposed. We also evaluated the references in the pertinent review articles and meta-analyses to identify other potentially eligible studies. The methodological quality of the studies was evaluated using the Newcastle–Ottawa scale. The maximum Newcastle–Ottawa scale score is 9: quality of selection (maximum, 4 stars), comparability (maximum, 2 stars), and exposure (maximum, 3 stars). A high-quality study was defined as a score equal to or greater than 7, and we defined a score from 4 to 6 as a moderate-quality study. All aspects of the study comply with the Declaration of Helsinki and the study was approved by the Ethics Committee of the Zhengzhou University People’s Hospital.

### 2.2. Inclusion criteria

A randomized controlled trial or an observational study was included if it met the following criteria: the weight changes in adult patients who were diagnosed with or self-reported DM were compared with those in controls; and adjusted and unadjusted mortality data were available. A published study was included if it included patients with clinical DM, measured weight losses/changes, compared weight-loss and control groups, had a follow-up period ≥2 years, and reported the adjusted effect size and its 95% confidence interval (CI). In cases of duplicate publications, we only included the most informative and complete studies. We did not include editorial letters, systematic reviews, meta-analyses, conference abstracts, and commentaries. Studies were deemed suitable only if they included full details of the statistical models, including the confounding factors. A list of the excluded studies and reasons for exclusion is provided in the table in Appendix 1; http://links.lww.com/MD/C453.

### 2.3. Data extraction and quality assessment

Data were extracted independently by 2 investigators (HJY and YQC) in May 2016. Discrepancies were resolved by consensus or according to the third author’s (XY) judgment. The search was repeated in February 2017 to identify any additional studies meeting the inclusion criteria. Authors were contacted in person, if required, to obtain further details regarding articles that met inclusion criteria. The results for each study were extracted for maximally adjusted models. We extracted the following data from each study: the first author’s name, publication year, study period, country or region where the study was conducted, sample size, weight change definition, the average participant age, the type of patients, initial BMI, diabetes duration, the manner of losing weight, comparison group, risk ratios (RRs) or hazard ratios (HRs) and 95% CIs for weight change categories, and variables adjusted for in the analysis (Tables 2–7).

### 2.4. Data analysis

In the examination of the associations of weight loss with all-cause mortality in overweight or obese diabetic individuals, the results are expressed as RRs with 95% CIs; RRs and HRs were included as eligible RRs without distinction because each provided effect sizes of a similar magnitude. Extracted HRs were recalibrated if the reference group was not weight stable. For example, if an article reported results for 4 different categories—such as weight stable-steady, weight stable-cyclic, weight gain, weight loss—and their reference category was weight loss, then the HRs would be recalibrated so that the weight stable-steady group would be the reference category. Extracted HRs were pooled when HRs for different groups were reported. For example, if an article reported results for 2 different categories, such as, weight loss HRs for men and women with diabetes, we pooled the HRs for all the participants with diabetes. Heterogeneity was assessed using the $I^2$ statistic; $P$ values <.05 were considered significant. Thus, we determined multivariate-adjusted RRs with 95% CIs using a random-effects model. Statistical analysis was performed using Review Manager [RevMan] [Computer program], Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. We performed a meta-analysis by removing 1 outcome at a time.

---

### Table 1

| Step | Syntax |
|------|--------|
| 1    | exp obesity/or exp obesity hyperventilation syndrome/or exp obesity, abdominal/or exp obesity, morbid/ |
| 2    | exp overweight/ |
| 3    | exp adipose tissue/ |
| 4    | exp weight gain/ |
| 5    | exp body fat distribution/or exp body mass index/or exp waist circumference/or exp skinfold thickness/or exp waist-hip ratio/ |
| 6    | exp body composition/or overweight$ or over weight$,tw,ot. |
| 7    | fat overload syndrome$,tw,ot. |
| 8    | overfeed$ or over feed$,tw,ot. |
| 9    | overeat$ or over eat$,tw,ot. |
| 10   | fat overload syndrome$,tw,ot. |
| 11   | body mass index$ or waist-hip ratio$,tw,ot. |
| 12   | skinfold thickness$,tw,ot. |
| 13   | abdominal fat$,tw,ot. |
| 14   | (abdominal or subcutaneous or intra-abdominal or visceral or retroperitoneal or retro panniculal adj 3 fat$),tw,ot. |
| 15   | or/1-16 |
| 16   | exp weight loss/ |
| 17   | weight loss,t,lab. |
| 18   | weight reduce$,t,lab. |
| 19   | or/18-20 |
| 20   | exp glucose tolerance test/or exp glucose intolerance/ |
| 21   | exp diabetes mellitus/ |
| 22   | exp insulin resistance/ |
| 23   | exp metabolic syndrome X/ |
| 24   | (impaired fasting adj 3 glucose or glycemia$),tw,ot. |
| 25   | glucose adj 3 (intolerance or tolerance test$),tw,ot. |
| 26   | or/22-33 |
| 27   | (impaired glucose adj 3 tolerant$ or stat$, or responsive$ or control$, or regul$, or metab$, or homeostasis$),tw,ot. |
| 28   | (reduced glucose adj 3 (metab$, or tolerant$),tw,ot. |
| 29   | (metabolic syndrome$ or syndrome X),tw,ot. |
| 30   | (borderline or mild) adj 3 diabetes$,tw,ot. |
| 31   | insulin resistant$,tw,ot. |
| 32   | or/22-33 |
| 33   | exp mortality/ |
| 34   | mortality$;tw,ot. |
| 35   | mortality$;tw,ot. |
| 36   | or/22-33 |
| 37   | mortalit$,tw,ot. |
| 38   | mortality$,tw,ot. |
| 39   | 17 and 21 and 34 and 38 |

---
to investigate whether each study contributed substantially to heterogeneity[^12] (Table 8). Publication bias was examined using Egger’s regression test.

3. Results

3.1. Study identification and selection

A total of 1348 studies were identified in the primary search after the removal of duplicate studies in May 2016. In all, 121 full-text articles were reviewed, of which 91 were excluded because the participants were not diabetics, 6 were excluded because weight changes were not reported, 8 were excluded because no long-term outcomes were reported, 2 were excluded because a control group was lacking, and 10 were excluded because no primary data were reported or because the publication was a review article. A total of 6 studies were included in the analysis.[^7,13-17] The search was repeated in February 2017, which yielded 201 studies published from May 2016 to February 2017, of which 173 were excluded as unrelated, 13 were excluded because the participants were not diabetics, and 4 were excluded because the results did not concern all-cause mortality. Two studies were added to the final analysis[^18,19] with a total of 8 studies included in the final analysis[^7,13-19] (Fig. 1).

3.2. Study characteristics

The included studies are summarized in Table 3. In total, these studies included 18,887 individuals with a mean follow-up period of 9.5 years. Two studies were conducted in the United States.[^14,16] One study was conducted in Germany, Italy, and the UK[^13]; 1 study was conducted in Native American Pima Indians.[^17], 1 was conducted in Europeans, East Asians, and Native Americans[^13]; and the remaining studies were conducted in southern California, Scotland or Denmark. The populations comprised middle-aged and older adults. In 2 studies, body weight and weight change were self-reported, which may cause high heterogeneity,[^7,14] and the remaining 6 studies measured weight and height at all visits. Tables 4 and 5 provide details on all-cause and cardiovascular mortality for each study and the estimates and corresponding 95% CIs extracted for each weight change category. All studies were cohort studies. The NOS results are shown in Table 2. The 8 included studies were all of high quality.

3.3. Weight loss

All 8 studies examined the relationship between weight loss and all-cause mortality in overweight or obese individuals with diabetes. The overall pooled relative risk of all-cause mortality for the weight loss group was 1.15 (95% CI, 1.04 to 1.28) (Fig. 2), which indicates that weight loss increased all-cause mortality in overweight or obese patients with diabetes. Moderate heterogeneity was significant among the estimates reported by the included studies (Q test, \(P=0.06, \text{I}^2=49\%\)). When the 2 studies in which weight change was self-reported were omitted, the result was 1.24 (95% CI, 1.10 to 1.39), and a significant decrease in heterogeneity was observed (Q test, \(P=0.36, \text{I}^2=9\%\)). Omitting 1 study at a time did not substantially change the overall results (Table 8).

Regarding the effect of the degree of weight loss on all-cause mortality in overweight or obese patients with diabetes, 4 studies had pertinent results[^7,14,16,17]; however, the studies used different measurements, the results of which are summarized in Table 6. As shown in this table, we found that the greater the weight loss, the greater the all-cause mortality.

The effect of weight loss on all-cause mortality differed for the category of initial BMI (Table 7). When the initial BMI was greater than 35 kg/m², weight loss was associated with increased all-cause mortality.[^7,13,17,18]

Five studies assessed the association between weight loss and cardiovascular disease (CVD) mortality[^7,14,17-19] and 3 assessed that between intentional weight loss and all-cause mortality.[^14,16,18] Compared to the reference group, an increased risk of CVD mortality was observed (HR, 1.15; 95% CI, 1.02 to 1.29), whereas intentional weight loss was not associated with all-cause mortality (HR, 0.90; 95% CI, 0.67 to 1.22). Notably,
| Study/year          | Country or population | Age, y | Patients | Sample size | F/u (y) | Wt. △ def. | Initial BMI, kg/m² | Diabetes duration, y | BMI measured | Wt. | Manner of losing weight | Study design |
|---------------------|-----------------------|--------|----------|-------------|---------|------------|-------------------|---------------------|--------------|-----|-----------------------|---------------|
| Chaturvedi and Fuller 1995 | Europe; East Asian; Native American | 35–55 | NIDDM | 992 | 13 | 2 kg/m² | 35% <26; 28% <29 kg/m²; 37% >29 kg/m² | Men = 8; Women = 9 | Measured | Not assessed | Cohort study |
| Williamson et al 2000 | United States | 40-64 | DM | 4970 | 12 | 1 lb | Unintentional gain: 29.9 ± 2.7 kg/m²; unintentional loss: 31.8 ± 4.1 kg/m²; intentional loss: 33 ± 5.0 kg/m² | Not given | Self-reported | Intentional weight loss; Unintentional weight loss | Cohort study |
| Wedick et al 2002 | Southern California | 40-79 | DM | 230 | 10 | 10 lb | Men 26.3 ± 3.0 kg/m²; women 24.6 ± 4.2 kg/m² | Not given | Measured | Dieting | Cohort study |
| Gregg et al 2004 | American | ≥35 | DM | 1401 | 9 | 1 lb | Mean 31.6 kg/m² | 10.5 | Measured | Attempted to lose weight | Cohort study |
| Doehner et al 2012 | Germany; Italy; UK | 62 ± 8 | T2DM; CVD | 5202 | 2.8 | 1% | Pioglitazone arm; 30.7 ± 4.7 kg/m²; placebo arm; 31.0 ± 4.8 kg/m² | 8 | Measured | Not assessed | Cohort study |
| Hanson et al 1999 | US: Native American; Pima Indian | 45.5 | DM | 814 | 8.1 | 1 kg/y | 56% ≥30 kg/m² | 4.7 | Measured | Not assessed | Cohort study |
| Aucott et al 2016 | Scotland | 58 | T2DM | 29316 | 5.2 | 1% | Mean 33.2 (SD = 6.0) kg/m² | Newly diagnosed between 2002 and 2006 | Measured | Not assessed | Cohort study |
| Køster-Rasmussen et al 2016 | Denmark | ≥40 | DM | 444 | 6 | 1 kg/y | Intention to lose weight: 32.6 ± 4.7 kg/m²; intention to maintain weight: 30.3 ± 4.0 kg/m² | Newly diagnosed in 1989–1992 | Measured | Intentional weight loss; Unintentional weight loss | Cohort study |

F/u = follow-up, Wt. △ def. = weight change definition, BMI = body mass index, CVD = cardiovascular disease, DM = diabetes mellitus, NIDDM = non-insulin dependent diabetes mellitus, T2DM = type 2 diabetes mellitus.
| Study/year               | Groups                                                                 | Fully adjusted RR (weight loss mortality) | Fully adjusted RR (weight gain mortality) | Pooled RR (weight loss mortality) | Pooled RR (weight gain mortality) | Fully adjusted RR (intentional weight loss mortality) | Comparison group                                                                 | Confounder adjustments                                                                 |
|-------------------------|------------------------------------------------------------------------|------------------------------------------|------------------------------------------|---------------------------------|---------------------------------|---------------------------------------------|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Chaturvedi and Fuller   | Initial BMI <26 kg/m²; initial BMI 26–29 kg/m²; initial BMI ≥29 kg/m²; | 3.05 (1.36–7.36); 2.02 (1.0–4.08); 0.84 (0.4–1.74) | 1.32 (0.56–3.11)                          | 0.78 (0.23–2.67); 0.73 (0.23–2.67); 1.74 (0.74–4.06) | 1.27 (0.56–2.88) | —                                           | Those whose BMI change was within +2 kg/m²                                           | Age, sex, and duration of diabetes                                                |
| Gregg et al 2004        | Weight loss/gain ≥1 lb; weight loss/gain 1–19 lb; weight loss/gain ≥20 lb | 1.19 (0.96–1.47); 1.09 (0.85–1.40); 1.36 (1.00–1.80) | 1.19 (0.96–1.47)                          | 1.10 (0.72–1.67); 1.00 (0.72–1.67); 1.48 (0.92–2.68) | 1.10 (0.72–1.67) | 0.83 (0.63–1.08)                             | Those who had no weight change and those who did not answer the weight change questions | Age, sex, race, smoking, initial BMI, education, drinking, physical activity, disease history, and current signs and symptoms |
| Wedick et al 2002       | Men; women                                                             | 3.85 (2.15–6.24); 1.22 (0.70–3.87)         | 2.28 (0.74–7.00)                          | —                               | —                               | —                                           | Those who lost <10 lb                                                            | Age, current or recent smoking, exercising <10 years earlier, and baseline BMI |
| Williamson et al 2007   | Unintentional loss ≥1 lb; intentional loss ≥1 lb                        | 0.98 (0.85–1.44); 0.75 (0.67–0.84)         | 0.83 (0.65–1.08)                          | 1.04 (0.79–1.36)                  | 1.04 (0.79–1.36) | 0.75 (0.67–0.84)                             | Those who were not trying to lose weight and who had stable weight or weight gain | Smoking, diabetes medications, duration of disease, functional limitations, hypertension, heart disease, stroke, retinal disease, neuropathy symptoms, hospital days, and doctor visits |
| Dehnherr et al 2012     | Weight loss/gain >1%                                                   | 1.13 (1.10–1.15)                          | 1.13 (1.10–1.15)                          | 0.97 (0.94–1.01)                  | 0.97 (0.94–1.01) | —                                           | Those whose weight was stable                                                   | Previous stroke, previous PCI or CABG, peripheral obstructive artery disease, smoking status, insulin use, diuretic use, and statin use |
| Hansen et al 1999       | Weight loss <−2 kg/y; weight loss −2 to −1 kg/y                         | 2.2 (1.4–3.3); 1.5 (1.1–2.1)               | 1.77 (1.22–2.56)                          | 1.6 (1.1–2.4)                    | 1.6 (1.1–2.4) | —                                           | Those who lost 1kg/2                                                                | Age, sex, smoking, probutamine, insulin therapy, duration of diabetes, year of baseline exam, time between exams, and BMI |
| Aucott et al 2016       | Loss: ≥10% 10% to 5%; 5% to 2.5% stable −2.5% to 2.5%; gain: 2.5% to 5% to 10% ≥2.5%      | 1.16 (0.64–1.55)                          | 1.16 (0.64–1.55)                          | 1.14 (0.80–1.59)                  | 1.14 (0.80–1.59) | —                                           | Those who had stable weight                                                      | Adjusted for patient characteristics, weight change patterns and antidiabetic medication regimes |
| Kester Rasmussen et al  | Intention to lose weight; intention to maintain weight; intention not well-described; aberrant weight pattern | 1.18 (1.06–1.33)                          | 1.18 (1.06–1.33)                          | —                               | —                               | 1.20 (0.97–1.50)                             | Those who lost 1kg/2                                                                | Adjustment for the use of acetylcholine esterase inhibitors or angiotensin receptor blockers did not change the association |

BMI = body mass index. CABG = coronary artery bypass grafting. PCI = percutaneous transluminal coronary intervention. RRs = relative risks.
heterogeneity existed for CVD mortality (Q test, \( P < 0.001, I^2 = 98\% \)), and all-cause mortality of intentional weight loss (Q test, \( P < 0.001, I^2 = 86\% \)) (Figs. 3 and 4).

### 3.4. Weight gain

A total of 6 studies investigated the association between weight gain and all-cause mortality.\(^{[7,13,14,16–18]}\) The overall pooled relative risk of all-cause mortality for the weight gain group was 1.17 (95% CI, 0.87 to 1.58; \( P = 0.31 \)) (Fig. 5), which signified that weight gain was not associated with all-cause mortality in overweight or obese patients with diabetes. High heterogeneity existed among the estimates reported by the included studies (Q test, \( P < 0.001, I^2 = 97\% \)). Omitting 1 study at a time did not substantially change the overall results. However, when 1 study was omitted, the heterogeneity decreased significantly (Q test, \( P = 0.77, I^2 = 0\% \)).

Four studies assessed the association between weight gain and CVD mortality.\(^{[7,14,17,18]}\) The overall pooled relative risk of CVD mortality for the weight gain group was 0.97 (95% CI, 0.93 to 1.01) (Fig. 6), which indicates that weight gain was not associated with CVD mortality in overweight or obese patients with diabetes. No heterogeneity existed among the estimates reported by the included studies (Q test, \( P = 0.59, I^2 = 0\% \)). No publication bias was identified using Egger’s test (\( P = 0.557 \)).

### 4. Discussion

To the best of our knowledge, this is the first meta-analysis to explore the effect of weight change on all-cause mortality in adult patients with diabetes. This study suggests that weight loss increased all-cause and CVD mortality in overweight or obese patients with diabetes, whereas weight gain was not associated with all-cause and CVD mortality.

“The obesity paradox” suggests that the relationship between excess adiposity and mortality is unclear, with recent data suggesting that individuals who have a normal weight at the time of DM diagnosis may have a greater mortality risk than their overweight or obese counterparts.\(^{[1]}\) Thus, weight loss may not be beneficial for overweight or obese individuals with diabetes.

People with T2DM have difficulty losing weight, for several reasons. In insulin-resistant conditions, hyperinsulinemia promotes triglyceride synthesis and storage while inhibiting lipolysis in adipocytes, resulting in an expansion of adipose tissue.\(^{[20]}\) People with diabetes may live sedentary lifestyles and not be very physically active.\(^{[21]}\) Moreover, some of the commonly used glucose-lowering drugs, such as insulin and the sulfonylurea drugs, are associated with weight gain, which further complicates successful weight management.\(^{[22]}\) The diligent control of blood glucose rather than weight loss might benefit diabetes and decrease cardiovascular risk factors.\(^{[23]}\) Finally, weight regain may result from the compensatory response to hormonal and metabolic changes following initial weight loss, wherein orexigenic mediators that stimulate appetite persist.\(^{[24]}\) Therefore, weight loss is an abnormal phenomenon and this observation is noteworthy because weight loss may indicate poorly controlled plasma glucose, more severe disease at baseline, or perhaps an occult systemic illness (i.e., malignancy) that manifested itself later in the disease course and resulted in harmful weight loss.\(^{[24]}\)

### Table 5

| Study/year | Fully adjusted RR (weight loss) | Pooled RR (weight loss) | Fully adjusted RR (weight gain) |
|------------|---------------------------------|------------------------|-------------------------------|
| Williamson et al 2000\(^{[16]}\) | Unintentional loss 0.98 (0.83–1.15) | 0.84 (0.62–1.13) | 0.90 (0.65–1.25) |
| Hanson et al 1995\(^{[17]}\) & Doehner et al 2012\(^{[7]}\) & Hanson et al 1995\(^{[17]}\) | 1.07 (1.03–1.10) | 0.97 (0.93–1.01) |
| Weight loss < –2 kg/y | 1.6 (0.6–4.1) | 1.6 (0.91–1.81) | 1.7 (0.7–3.9) |
| Weight loss > 2 to –1 kg/y | 1.6 (0.8–3.2) | 0.92 (0.7–1.22) | Myocardial infarction 0.96 (0.63–1.57) |
| Myocardial infarction 1.02 (0.63–1.57) | 1.03 (0.56–1.82) | Congestive heart failure 0.99 (0.61–1.60) |
| Peripheral vascular disease 0.62 (0.54–1.86) | Cerebrovascular disease 1.02 (0.59–1.76) |
| Cerebrovascular disease 1.03 (0.52–1.95) |  |
| Koster-Rasmussen et al 2016\(^{[19]}\) | 1.12 (0.97–1.30) | 1.12 (0.97–1.30) | — |

The comparison groups and confounder adjustments are the same as in Table 4. RR = relative risks.

### Table 6

| Study/year | Gregg et al 2004\(^{[18]}\) | Williamson et al 2000\(^{[16]}\) | Doehner et al 2012\(^{[7]}\) | Hanson et al 1995\(^{[17]}\) |
|------------|-----------------------------|-------------------------------|-------------------------------|-------------------------------|
| Weight loss levels | Weight loss 1–19 lb 1.09 (0.85–1.40) | Intentional weight loss was most protective at a loss of 20–29 lb 0.67 (0.58–0.77) | Weight loss >5% 3.25 (2.51–4.21) | Weight loss =2 to –1 kg/y 1.5 (1.1–2.1) |
| Weight loss ≥20 lb 1.36 (1.03–1.80) | Weight loss ≥6% 3.56 (2.77–4.79) | Weight loss =7.5% 4.42 (3.30–5.94) | Weight loss ≥10% 5.60 (3.96–7.91) | Weight loss ≥15% 7.72 (4.73–12.60) |

HR = hazard ratio.
Other reasons might explain the association of weight loss with increased all-cause mortality in overweight or obese individuals with diabetes. First, our sample was composed of middle-aged and older adults. Muscle mass decreases with age and concurrently, fat mass, particularly the proportion of visceral and abdominal fat, increases. Moreover, weight loss via energy restriction may do little to alter the relative distribution of body fat and may result in decreased muscle mass, which is harmful for middle-aged and older adults. Second, diabetic patients had significantly higher scores for depressed mood than those without DM. Depression has been linked to weight loss and mortality. Third, some studies suggested that 1 possible explanation for the association of weight loss and higher mortality was occult disease. Our study also found that intentional weight loss did not increase all-cause mortality in overweight or obese adults with diabetes. In a recent meta-analysis, Harrington found an increased risk of all-cause mortality regardless of the intentional or unintentional nature of the weight loss among healthy participants; however, intentional weight loss had a small benefit for individuals classified as unhealthy (i.e., with obesity-related risk factors). The Look AHEAD Research Group found that intensive lifestyle intervention also produced greater reductions in hemoglobin A1c and greater initial improvements in fitness and all cardiovascular risk factors, except LDL cholesterol. Intentional weight loss may benefit diabetic patients for 2 possible reasons. First, patients who intend to lose weight may become more motivated to make a series of lifestyle changes, such as reducing their fat intake or increasing their exercise level. Such changes may decrease mortality by benefiting an individual’s overall health status. Second, these individuals may become more likely to engage in positive health behaviors unrelated to weight (e.g., getting adequate sleep, not smoking), have more frequent contact with health care providers and participate in preventive care practices, such as early disease screening and treatment. However, only 3 such studies were included in the analysis, and high heterogeneity was observed (Q test, \( P < 0.001 \), \( I^2 = 86\% \)). In the future, well-designed studies that identify whether weight loss intention modifies the association between weight loss and all-cause mortality in overweight or obese patients with diabetes will be required to better understand the underlying pathways.

Our findings show that weight gain was not associated with changes in all-cause mortality or CVD mortality in overweight or obese adults with diabetes. The term “obesity paradox” has been coined to describe this association, which is supported by a large amount of data assembled from patients with DM or CVD showing that overweight and obesity are actually associated with prolonged survival. Conversely, weight loss is a characteristic feature of advanced illness, such as DM or CVD, and weight gain may therefore reflect reduce catabolic activity and restored anabolic capacity. In addition, some therapies, such as insulin, sulfonylurea drugs, ACE inhibitors and beta-blockers, are highly effective in improving survival in patients with DM or CVD and have been shown to produce weight gain. In spite of these data, our results indicate that all-cause mortality gradually increases when the initial BMI >35 kg/m\(^2\), suggesting that not all weight gain is associated with reduced mortality (Table 7). Thus, more research and data are needed to support the effect of weight gain on all-cause mortality in overweight or obese individuals with diabetes.

The studies included in this analysis had different inclusion criteria, such as the initial BMI, degree of weight change, sex, race, and weight-loss intent; for example, 5 different definitions of weight change were encountered, that is, a weight change of >2 kg/m\(^2\), 1 lb, 10 lb, 1% or 1 kg/y, and these differences may have contributed to the high heterogeneity observed. Two studies were conducted in the United States and the remaining studies were conducted in different countries. One of the studies included patients with T2DM and cardiovascular comorbidities, another included patients with T2DM only, and the remaining 4 studies included patients with DM; these differences may also have contributed to the high heterogeneity. When the study that included patients with T2DM and cardiovascular co-morbidities was omitted, the results were as follows: RR, 1.16; 95% CI, 1.06 to 1.27; \( I^2 = 55\% \), \( P = 0.001 \). A well-designed prospective study is necessary to conclusively determine the importance of weight loss in patients with established DM. Such a study should be adequately powered for long-term outcomes and should carefully assess body composition changes.
Figure 1. Figure legends.

- Records identified through database searching (n = 1348)
- Additional records identified through other sources (n = 2)
- Records after duplicates removed (n = 1253)
- Records screened (n = 1253)
- Full-text articles assessed for eligibility (n = 123)
- Studies included in qualitative synthesis (n = 6)
- Studies included in quantitative synthesis (meta-analysis) (n = 8)
- Records excluded (content not relevant) (n = 1130)
- Full-text articles excluded as specified (n = 117)
  - 91: Patients without DM
  - 6: Weight change(s) not reported
  - 8: No long-term outcomes reported
  - 2: No comparison group
  - 10: No primary data reported/review article
- Repeated the search and included additional studies (n = 2)

Figure 2. Forest plot showing the effect of weight loss on all-cause mortality.
### Figure 3.
Forest plot showing the effect of weight loss on cardiovascular disease (CVD) mortality.

| Study or Subgroup       | log[Hazard Ratio] | SE  | Weight | Hazard Ratio IV Random 95% CI       | Hazard Ratio IV Random 95% CI |
|-------------------------|-------------------|-----|--------|------------------------------------|--------------------------------|
| Aucott et al. 2016      | 0.13203526        | 0.18527837 | 16.6%  | 1.14 [0.81, 1.61]                  |                                |
| Chatuvodi and Fuller 1995 | 0.29305069      | 0.82773972 | 8.2%   | 1.27 [0.56, 2.88]                  |                                |
| Doehner et al. 2012     | -0.010945921     | 0.01632889 | 21.2%  | 0.97 [0.94, 1.01]                  |                                |
| Gregg and Gerzoff 2004  | 0.09531018       | 0.21462441 | 15.0%  | 1.10 [0.72, 1.68]                  |                                |
| Hanson et al. 1995      | 0.47003635       | 0.03065153 | 21.0%  | 1.16 [1.51, 1.70]                  |                                |
| Williamson et al. 2000  | 0.09322071       | 0.13653232 | 18.1%  | 1.04 [0.79, 1.36]                  |                                |
| Total (95% CI)          | 100.0%            |      |        | 1.17 [0.87, 1.58]                  |                                |
| Heterogeneity: Tau² = 0.11; Chi² = 197.60, df = 5 (P < 0.00001); I² = 97% | | | | |
| Test for overall effect: Z = 1.02 (P = 0.31) | | | | |

### Figure 4.
Forest plot showing the effect of intentional weight loss on all-cause mortality.

| Study or Subgroup       | log[Hazard Ratio] | SE  | Weight | Hazard Ratio IV Random 95% CI       | Hazard Ratio IV Random 95% CI |
|-------------------------|-------------------|-----|--------|------------------------------------|--------------------------------|
| Aucott et al. 2016      | -0.09298329       | 0.00883475 | 5.6%   | 0.95 [0.80, 1.12]                  |                                |
| Doehner et al. 2012     | -0.03045921      | 0.02105128 | 92.7%  | 0.97 [0.93, 1.01]                  |                                |
| Hanson et al. 1995      | 0.53062825       | 0.4381764 | 0.2%   | 1.70 [0.72, 4.01]                  |                                |
| Williamson et al. 2000  | -0.10536052      | 0.16681798 | 1.5%   | 0.90 [0.65, 1.25]                  |                                |
| Total (95% CI)          | 100.0%            |      |        | 0.97 [0.93, 1.01]                  |                                |
| Heterogeneity: Tau² = 0.00; Chi² = 1.90, df = 3 (P = 0.59); I² = 0% | | | | |
| Test for overall effect: Z = 1.56 (P = 0.12) | | | | |

### Figure 5.
Forest plot showing the effect of weight gain on cardiovascular disease (CVD) mortality.

### Figure 6.
Forest plot showing the effect of weight gain on all-cause mortality.
use behavioral weight-loss strategies, encourage high-calorie expenditure exercise (e.g., walking frequently, walking long distances), and carefully control for cancer development and smoking cessation. Such a study would provide more conclusive evidence of the effect of intentional weight loss on the prognosis of patients with diabetes, answer multiple remaining questions, increase confidence in weight-management recommendations for patients with diabetes, and further clarify the obesity paradox. Additionally, given the known benefits of bariatric surgery in the general population, a randomized controlled trial of bariatric surgery in patients with diabetes might also be appropriate.

4.1. Limitations of the study
This meta-analysis was limited by the small number of studies included and the sample sizes, both of which increased the difficulty in performing subgroup analyses. Another potential limitation was that weight was measured directly in some studies and was self-reported in others.

5. Conclusion
Considering the limitations of this analysis, the evidence suggested that weight loss but not weight gain increased all-cause mortality and CVD mortality in overweight or obese patients with diabetes. In the future, studies using larger sample sizes and more accurate measurements of weight will be required to examine the relationship between weight loss and all-cause mortality in overweight or obese patients with diabetes.

Author contributions
Conceptualization: Yangshiyu Li, Huijuan Yuan.
Data curation: Yiqi Chen, Huijuan Yuan.
Formal analysis: YiQi Chen, Yangshiyu Li, Huijuan Yuan.
Investigation: Yiqi Chen, Juyang Wang.
Methodology: YiQi Chen, Juyang Wang.
Project administration: Huijuan Yuan.
Software: Juyang Wang, Dou Ying.
Supervision: Xue Yang, Dou Ying.
Validation: Xue Yang.
Visualization: Yangshiyu Li, Dou Ying.
Writing – original draft: YiQi Chen, Huijuan Yuan.
Writing – review & editing: Xue Yang, Juyang Wang, Yangshiyu Li, Dou Ying.

References
[1] Carnethon MR, De Chavez PJ, Biggs ML, et al. Association of weight status with mortality in adults with incident diabetes. JAMA 2012;308:581–90.
[2] Wing RR, Bolin P, Brancati FL, et al. Look AHEAD Research Group/Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145–54.
[3] Krichhevsky SB, Beavers KM, Miller ME, et al. Intentional weight loss and all-cause mortality: a meta-analysis of randomized clinical trials. PLOS ONE 2015;10:e121993.
[4] Cheng FW, Gao X, Jensen GL. Weight change and all-cause mortality in older adults: a meta-analysis. J Nutr Gerontol Geriatr 2015;34:343–68.
[5] Hong N, Yoon HJ, Lee YH, et al. Serum PTHrP predicts weight loss in cancer patients independent of hypercalcemia, inflammation, and tumor burden. J Clin Endocrinol Metab 2016;101:1207–14.
[6] Brown RE, Kuk JL. Consequences of obesity and weight loss: a devil’s advocate position. Obes Rev 2015;16:77–87.
[7] Doehner W, Erdmann E, Cairns R, et al. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROActive study population. Int J Cardiol 2012;162:20–6.
[8] Costanzo P, Cleland JG, Pellicioni P, et al. The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort burden. J Clin Endocrinol Metab 2015;101:610–8.
[9] Oreopoulos A, Padwal R, Kalantar-Zadeh K, et al. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 2008;156:13–22.
[10] Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:1–30.
[11] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.
[12] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
[13] Chaturvedi N, Fuller JH. Mortality risk by body weight and weight change in people with NIDDM. The WHO multinational study of vascular disease in diabetes. Diabetes Care 1995;18:766–74.
[14] Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499–504.
[15] Wedick NM, Barrett-Connor E, Knoke JD, et al. The relationship between weight loss and all-cause mortality in older men and women with and without diabetes mellitus: the Rancho Bernardo study. J Am Geriatr Soc 2002;50:1810–5.
[16] Gregg EW, Gezoff RB, Thompson TJ, et al. Trying to lose weight, losing weight, and 9-year mortality in overweight U.S. adults with diabetes. Diabetes Care 2004;27:657–62.
[17] Hanson RL, McCance DR, Jacobson LT, et al. The U-shaped association between body mass index and mortality: relationship with weight gain in a Native American population. J Clin Epidemiol 1995;48:903–16.
[18] Aucott LS, Philip S, Avenell A, et al. Patterns of weight change after the diagnosis of type 2 diabetes in Scotland and their relationship with glycemic control, mortality and cardiovascular outcomes: a retrospective cohort study. BMJ Open 2016;6:e10836.
[19] Koster-Rasmussen R, Simonsen MK, Siersma V, et al. Intentional weight loss and longevity in overweight patients with Type 2 diabetes: a population-based cohort study. PLOS One 2016;11:e146889.
[20] Yubero-Serrano EM, Delgado-Listo J, Tierney AC, et al. Insulin resistance determines a differential response to changes in dietary fat modification on metabolic syndrome risk factors: the LIPGENE study. Am J Clin Nutr 2015;102:1509–17.
[21] Faierza MF, Wang DQ, Frishbeck G, et al. The dangerous link between childhood and adulthood predictors of obesity and metabolic syndrome. Intern Emerg Med 2016;11:173–82.
[22] Loo DC, Teoh H. Impact of current and emerging glucose-lowering drugs on body weight in Type 2 diabetes. Can J Diabetes 2015;39(suppl 5):S48–54.
[23] Kattel S, Kasiati T, Matsumoto H, et al. Association between elevated blood glucose level on admission and long-term mortality in patients with acute decompensated heart failure. J Cardiol 2017;69:619–24.
[24] Cares RA, Borashok J, Taylor M, et al. A randomized trial comparing two approaches to weight loss. J Health Psychol 2017;22:943–50.
[25] Myers J, Lata K, Chowdhury S, et al. The obesity paradox and weight loss. Am J Med 2011;124:924–30.
[26] Tyrovoulos S, Haro JM, Mariolis A, et al. Skeletal muscle mass and body fat in relation to successful ageing of older adults: the multi-national MEDIS study. Arch Gerontol Geriatr 2016;66:95–101.
[27] Cola-Sagarra C, López-Simarro F, Alonso-Fernández M, et al. Prevalence of depression in patients with type 2 diabetes attended in primary care in Spain. Prim Care Diabetes 2016;10:369–75.
[28] Naicker K, Johnson JA, Skogen JC, et al. Type 2 diabetes and comorbid symptoms of depression and anxiety: longitudinal associations with mortality risk. Diabetes Care 2017;40:352–8.
[29] Harrington M, Gibson S, Cottrell RC. A review and meta-analysis of the effect of weight loss on all-cause mortality risk. Nutr Res Rev 2009;22:93–108.
[30] Gregg EW, Jakicic J, Blackburn G, et al. Look AHEAD Research Group/Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016;4:913–21.
[31] Clark AL, Fonarow GC, Horwich TB. Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis 2014;56:409–14.